Altium Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Altium Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$169K	Hold	16,000	–	–	0.01%	351
2022 Q1	$260K	Hold	16,000	–	–	0.02%	328
2021 Q4	$222K	Hold	16,000	–	–	0.01%	351
2021 Q3	$230K	Buy	16,000 +1,000	+7%	+$15.8K	0.02%	340
2021 Q2	$237K	Hold	15,000	–	–	0.02%	342
2021 Q1	$153K	Sell	15,000 -350	-2%	-$3.61K	0.01%	366
2020 Q4	$114K	Buy	15,350 +5,000	+48%	+$25.8K	0.01%	341
2020 Q3	$36K	Buy	+10,350	New	+$44.4K	﹤0.01%	336

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Altium Wealth Management's BCRX Position: Q2 2022 in Review

Altium Wealth Management held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2022 at 16,000 shares worth $169K. The position accounts for 0.01% of the portfolio, ranked #351.

Altium Wealth Management first reported a position in BCRX in Q3 2020 and has held it in 8 quarters since. The position peaked at $260K in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

Altium Wealth Management held 16,000 shares of BioCryst Pharmaceuticals worth $169K as of Q2 2022.
Altium Wealth Management left its BioCryst Pharmaceuticals share count unchanged in Q2 2022.
BioCryst Pharmaceuticals made up 0.01% of Altium Wealth Management's portfolio in Q2 2022, its #351 holding.
Altium Wealth Management first reported a position in BioCryst Pharmaceuticals in Q3 2020 and has held it in 8 quarters since.
Altium Wealth Management's BioCryst Pharmaceuticals position peaked at $260K in Q1 2022.
221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Altium Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.